Cancer Research Campaign adjuvant breast trial for patients over the age of 50

INTERVENTION: Patients receive primary surgical and irradiation treatments as are felt appropriate and are started on tamoxifen 20 mg daily. Patients event‐free and consenting at 2 years are randomised into one of two treatment groups: 1. Group A: Stop tamoxifen 2. Group B: Continue tamoxifen therapy for a further 3 years CONDITION: Breast ; Cancer ; Breast PRIMARY OUTCOME: Not provided at time of registration SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Aged >50 years and <70 years (revised to <80 years in February 1991) 2. Operable breast cancer (clinically T1, T2 or T3, N0 or N1, M0) 3. No evidence of metastases 4. Normal renal and hepatic function, and full blood counts, including platelets 5. Patients with bilateral tumours are not eligible 6. No concomitant hormonal therapy or chemotherapy 7. No previous malignancy, except basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix adequately cone biopsied 8. Patients whose axillary nodes demonstrate deep fixity are not eligible 9. Patients whose primary cancer is fixed to the underlying muscle or chest wall, or those with ulceration, skin infiltration, peau d'orange or satellite skin nodules are not eligible 10. Fit to receive either treatment